The N6 ‐methyladenosine reader IGF2BP3 promotes bladder cancer progression through enhancing HSP90AB1 expression
The FEBS Journal · 2025
DOI: 10.1111/febs.70068 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2025. Verfasst von Xiaoqing Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Adenosine, RNA-Binding Proteins, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Nanjing Medical Science and technology development Foundation, Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
N 6 ‐methyladenosine (m 6 A) is the most abundant RNA modification in mammalian cells, and has emerged as an important player in tumour development through post‐transcriptional gene regulation. In this study, we found that the m 6 A reader protein IGF2BP3 was the most upregulated m 6 A modifier in bladder cancer through the proteomic analysis of 17 pairs of human bladder cancer tissues and adjacent normal bladder tissues, for which the expression was also positively correlated with higher tumour stage and poorer prognosis. In vitro and in vivo assays demonstrated the powerful oncogenic function of IGF2BP3 in bladder cancer. Further combined analyses of RNA‐sequencing, m 6 A‐sequencing, and RIP (RNA Binding Protein Immunoprecipitation)‐sequencing, as well as site‐directed mutagenesis assays and RIP‐qPCR identified m 6 A‐tagged HSP90AB1 mRNA as a direct target of IGF2BP3. Mechanistically, through in vitro and in vivo assays, as well as clinical sample analysis, we demonstrated that IGF2BP3 modulated the expression of HSP90AB1 in an m 6 A modification‐dependent manner, thus activating the PI3K/AKT‐signaling pathway, and promoting the development of bladder cancer. Collectively, our study highlights the critical role of the IGF2BP3‐HSP90AB1‐signaling axis in bladder cancer progression, which may serve as a promising therapeutic approach for bladder cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, China.
- Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, China.
ORCID-Profile: Qing Zhang, Meng Ding, Hongqian Guo
Förderung
- Nanjing Medical Science and technology development Foundation
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Chen, X., Diao, W., Guo, X., Cao, W., Yang, Y., Xie, T., Chen, W., Yang, L., Zhang, Q., Ding, M., & Guo, H. (2025). The N6 ‐methyladenosine reader IGF2BP3 promotes bladder cancer progression through enhancing HSP90AB1 expression. The FEBS Journal. https://doi.org/10.1111/febs.70068
Vancouver
Chen X, Diao W, Guo X, Cao W, Yang Y, Xie T, et al. The N6 ‐methyladenosine reader IGF2BP3 promotes bladder cancer progression through enhancing HSP90AB1 expression. The FEBS Journal. 2025. doi:10.1111/febs.70068
BibTeX
@article{Chen2025,
author = {Chen, Xiaoqing and Diao, Wenli and Guo, Xinyue and Cao, Wenmin and Yang, Yang and Xie, Tianlei and Chen, Wei and Yang, Lin and Zhang, Qing and Ding, Meng and Guo, Hongqian},
title = {The N6 ‐methyladenosine reader IGF2BP3 promotes bladder cancer progression through enhancing HSP90AB1 expression},
journal = {The FEBS Journal},
year = {2025},
doi = {10.1111/febs.70068}
}
EUVIMED